Rahul Banerjee, MD

Dr Rahul Banerjee | Image Credit: Fred Hutch Cancer Center

Rahul Banerjee, MD, is an assistant professor at the Fred Hutchinson Cancer Center.

Articles by Rahul Banerjee, MD

Rahul Banerjee, MD, FACP | Image Credit: © Fred Hutch Cancer Center

Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD

July 21st 2026

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab.

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, but Longer Follow-Up Needed: Rahul Banerjee, MD

ByBrooke McCormick,Rahul Banerjee, MD

July 4th 2026

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

EHA 2026 Congress recap | Image Credit: Brooke McCormick

Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

ByBrooke McCormick,Nitin Jain, MD,Irina Murakhovskaya, MD,Rahul Banerjee, MD,Julie Kanter, MD

June 18th 2026

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

ByBrooke McCormick,Rahul Banerjee, MD

June 13th 2026

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

Rahul Banerjee, MD

Articles by Rahul Banerjee, MD

Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, but Longer Follow-Up Needed: Rahul Banerjee, MD

Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Latest Updated Articles

Trending on AJMC

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Dermatology Practices Absorb Rising Prior Authorization Costs